Barry Quart Sells 12,528 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 12,528 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total transaction of $567,142.56. Following the sale, the director owned 12,546 shares in the company, valued at $567,957.42. This represents a 49.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $42.58 on Friday. The firm’s 50-day simple moving average is $41.80 and its 200-day simple moving average is $38.13. Kiniksa Pharmaceuticals International, plc has a twelve month low of $18.12 and a twelve month high of $45.50. The firm has a market cap of $3.23 billion, a P/E ratio of 94.62 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The business had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same period last year, the company earned ($0.18) EPS. On average, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.33.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its position in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Mariner LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 5.8% during the third quarter. Mariner LLC now owns 13,253 shares of the company’s stock valued at $515,000 after acquiring an additional 732 shares during the period. CWM LLC boosted its holdings in Kiniksa Pharmaceuticals International by 3.9% in the fourth quarter. CWM LLC now owns 20,605 shares of the company’s stock valued at $850,000 after acquiring an additional 764 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Kiniksa Pharmaceuticals International by 4.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after acquiring an additional 771 shares during the last quarter. Finally, USA Financial Formulas acquired a new stake in Kiniksa Pharmaceuticals International in the third quarter worth about $32,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.